Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens

Blood

Volumn 117, Issue 6, 2011, Pages 1799-1805

  Montesinos, Pau ^a   Rayón, Chelo ^b   Vellenga, Edo ^c   Brunet, Salut ^d   González, José ^e   González, Marcos ^f   Holowiecka, Aleksandra ^g   Esteve, Jordi ^h   Bergua, Juan ⁱ   González, José D ^j   Rivas, Concha ^k   Tormo, Mar ^l   Rubio, Vicente ^m   Bueno, Javier ⁿ   Manso, Félix ^o   Milone, Gustavo ^p   De La Serna, Javier ^q   Pérez, Inmaculada ^r   Pérez Encinas, Manuel ^s   Krsnik, Isabel ^t   Ribera, Josep M ^u   Escoda, Lourdes ^v   Lowenberg, Bob ^w   Sanz, Miguel A ^a   more..

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^f HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^g INSTITUTE OF ONCOLOGY   (Poland)

^h HOSPITAL CLÍNIC   (Spain)

ⁱ HOSPITAL SAN PEDRO DE ALCÁNTARA   (Spain)

^j HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

^k HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^l HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^m HOSPITAL DE JEREZ   (Spain)

ⁿ HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^o HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^p Fundacion para Combatir La Leucemia   (Argentina)

^q HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^r HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^s Pediatric Nutrition Research Group Health Research Institute of Santiago de Compostela   (Spain)

^t HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^u HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^v HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^w ERASMUS MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTHRACYCLINE; CD15 ANTIGEN; CD2 ANTIGEN; CD34 ANTIGEN; CD56 ANTIGEN; CD7 ANTIGEN; CYTARABINE; HLA DR ANTIGEN; IDARUBICIN; MITOXANTRONE; RETINOIC ACID; STEM CELL FACTOR RECEPTOR; T LYMPHOCYTE ANTIGEN;

ADULT; ADVERSE OUTCOME; AGED; ALBUMIN BLOOD LEVEL; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; EXTRAMEDULLARY HEMATOPOIESIS; FEMALE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; RECURRENCE RISK;

EID: 79951503141     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-04-277434     Document Type: Article

References (29)

1. Murray CK, Estey E, Paietta E, et al. CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome? J Clin Oncol. 1999;17(1):293-297.
2. Ferrara F, Morabito F, Martino B, et al. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy. J Clin Oncol. 2000;18(6):1295-1300. (Pubitemid 30159848)
3. Ito S, Ishida Y, Oyake T, Satoh M, et al. Clinical and biological significance of CD56 antigen expression in acute promyelocytic leukemia. Leuk Lymphoma. 2004;45(9):1783-1789. (Pubitemid 38997144)
4. Albano F, Mestice A, Pannunzio A, et al. The biological characteristics of CD34+ CD2+ adult acute promyelocytic leukemia and the CD34 CD2 hypergranular (M3) and microgranular (M3v) phenotypes. Haematologica. 2006;91(3):311-316.
5. Paietta E, Goloubeva O, Neuberg D, et al.Asurrogate marker profile for PML/RAR alpha expressing acute promyelocytic leukemia and the association of immunophenotypic markers with morphologic and molecular subtypes. Cytometry B Clin Cytom. 2004;59(1):1-9. (Pubitemid 38581544)
6. Sanz MA, Martin G, Gonzalez M, et al. Riskadapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004;103(4):1237-1243. (Pubitemid 38168633)
7. Sanz MA, Montesinos P, Rayon C, et al. Riskadapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood. 2010;115(25):5137-5146.
8. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9(10):1783-1786.
9. Guglielmi C, Martelli MP, Diverio D, et al. Immunophenotype of adult and childhood acute promyelocytic leukaemia: correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases. Br J Haematol. 1998;102(4):1035-1041. (Pubitemid 28410536)
10. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642-4649. (Pubitemid 46594039)
11. Bolufer P, Barragan E, Sanz MA, et al. Preliminary experience in external quality control of RT-PCR PML-RAR alpha detection in promyelocytic leukemia. Leukemia. 1998;12(12):2024-2028. (Pubitemid 28554475)
12. Montesinos P, Bergua JM, Vellenga E, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood. 2009;113(4):775-783.
13. Cervera J, Montesinos P, Hernández-Rivas JM, et al. Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Haematologica. 2010;95(3):424-431.
14. Sanz MA, Lo Coco F, Martin G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96(4):1247-1253. (Pubitemid 30658450)
15. Kaplan EL, Meier P. Nonparametric estimations from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
16. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50(3):163-170.
17. Gray RJ. A class of K-sample test for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16(3):1141-1154.
18. Pepe MS, Mori M. Kaplan-Meier, marginal or conditional probability curves in summarizing competing risk failure time data? Stat Med. 1993;12(8):737-751.
19. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B. 1972;34:187-220.
20. Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
21. Lee ET. Statistical Methods for Survival Data Analysis. Vermont, CA: Wadsworth Inc; 1980.
22. Chapiro E, Delabesse E, Asnafi V, et al. Expression of T-lineage-affiliated transcripts and TCR rearrangements in acute promyelocytic leukemia: implications for the cellular target of t(15;17). Blood. 2006;108(10):3484-3493.
23. de la Serna J, Montesinos P, Vellenga E, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood. 2008;111(7):3395-3402.
24. Raspadori D, Damiani D, Lenoci M, et al. CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia. 2001;15(8):1161-1164. (Pubitemid 32776438)
25. Xu N, Liu XL, DU QF, et al. CD56 and CD11b antigen expressions in patients with acute monocytic leukemia and the clinical implications. Nan Fang Yi Ke Da Xue Xue Bao. 2009;29(8):1605-1608.
26. Ando T, Mitani N, Matsui K, et al. Recurrent extramedullary relapse of acute myelogenous leukemia after allogeneic hematopoietic stem cell transplantation in a patient with the chromosomal abnormality t(8;21) and CD56-positivity. Int J Hematol. 2009;90(3):374-377.
27. Chang H, Brandwein J, Yi QL, et al. Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome. Leuk Res. 2004;28(10):1007-1011. (Pubitemid 39037332)
28. Baer MR, Stewart CC, Lawrence D, et al. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22; q22). Blood. 1997;90(4):1643-1648. (Pubitemid 27355438)
29. Tallman MS. Extramedullary acute myeloid leukemia infiltrates. Leuk Res. 2004;28(10):1005-1006. (Pubitemid 39037331)